Holen Sie sich die Stockscreener-App
5.63
2.93%
-0.17
Handel nachbörslich:
5.63
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RCEL?
Forum
Prognose
Aktiensplit
Avita Medical Inc Aktie (RCEL) Neueste Nachrichten
Avita raises AU$23M to grow Recell wound portfolio - BioWorld MedTech
Lake Street Capital Issues Pessimistic Forecast for Avita Medical (NASDAQ:RCEL) Stock Price - MarketBeat
Avita Medical shares rise 1.56% intraday after a special call webinar. - AInvest
News Flash: 10 Analysts Think AVITA Medical, Inc. (NASDAQ:RCEL) Earnings Are Under Threat - 富途牛牛
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation - ADVFN Brasil
Wall Street Zen Downgrades Avita Medical (NASDAQ:RCEL) to Sell - MarketBeat
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Avita Medical: Equity Raise Derisks Runway to Positive Cash Flow - Morningstar
Analysts Are More Bearish On AVITA Medical, Inc. (NASDAQ:RCEL) Than They Used To Be - Yahoo Finance
Institutional Tools Highlight Unusual Flow in AVITA Medical Inc.2025 Support & Resistance & Safe Capital Growth Tips - sundaytimes.kr
Avita Medical (NASDAQ:RCEL) Rating Lowered to "Sell" at BTIG Research - MarketBeat
Avita’s Road to Profitability Is in Sight - Morningstar
Avita Medical Raises $15M Through Australian Equity Placement - AInvest
Avita Medical says it completed Australian equity raise - MarketScreener
Avita Medical shares rise 3.44% after-hours after completing a private placement of approximately 17.2 million new CHESS Depositary Interests. - AInvest
Avita Medical (NASDAQ:RCEL) Price Target Cut to $18.00 by Analysts at D. Boral Capital - MarketBeat
AVITA Medical Successfully Completes Australian Equity Raise | RCEL Stock News - GuruFocus
AVITA Medical Successfully Completes Australian Equity Raise - The Manila Times
AVITA Medical completes Australian equity raise, raising $23 million. - AInvest
AVITA Medical Raises US$15M from Australian Investors to Fuel Growth Until Cash Flow Positive - Stock Titan
Evernest Financial Advisors LLC Buys New Position in Avita Medical Inc. (NASDAQ:RCEL) - MarketBeat
Dr. Michael Tarnoff - DOTmed
Analyst Jason Kolbert Lowers Price Target for AVITA Medical to $18.00 - AInvest
AVITA Medical to Host Investor Webinar Briefing on Q2 Earnings - AInvest
AVITA Medical: Lake Street maintains Buy, PT down to $8 from $14. - AInvest
Lake Street Capital Markets assumes coverage on Avita Medical stock with Buy rating - Investing.com Canada
Avita Medical shares rise 3.29% premarket after announcing an investor webinar briefing. - AInvest
Visualizing AVITA Medical Inc. stock with heatmapsShort-Term Swing Opportunity Summary Sheet - Newser
Avita Medical (NASDAQ:RCEL) Cut to Sell at BTIG Research - Defense World
What momentum shifts mean for AVITA Medical Inc.Real-Time Equity Price Action Analysis - Newser
Full technical analysis of AVITA Medical Inc. stockFree Investment Plan With Growth Optimization - Newser
AVITA Medical to Host Investor Webinar: Financial and Business Update - AInvest
AVITA Medical to Host Investor Webinar Briefing - The Manila Times
AVITA Medical CEO to Present Q2 Earnings Deep Dive: How to Join the Upcoming Investor Briefing - Stock Titan
AVITA Medical (RCEL.O) Suffers 21% Drop: A Technical and Order-Flow Deep Dive - AInvest
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25% - simplywall.st
Avita projects $76M–$81M 2025 revenue with rebound expected as claims backlog eases - MSN
Lower fair value for undervalued ASX share - Morningstar
Avita Medical Q2 2025 Revenue at $18.4M, Projects $76M-$81M 2025 Revenue with Backlog Easing - AInvest
AVITA Medical 2025 Q2 Earnings Narrowed Losses, Revenues Up but Guidance Cut - AInvest
Is AVITA Medical Inc. forming a bottoming baseBollinger Band Squeeze and Expansion Analysis - Newser
Orica Limited Updates on Share Buy-Back Progress - The Globe and Mail
Avita Medical shares rise 2.82% after-hours after revising earnings guidance for 2025. - AInvest
Avita Medical: Navigating Short-Term Reimbursement Headwinds, Unlocking Long-Term Growth in Acute Wound Care - AInvest
BTIG Downgrades Avita Medical(RCEL.US) to Sell Rating, Announces Target Price $3 - 富途牛牛
Form 424B5 AVITA Medical, Inc. - StreetInsider
BTIG Downgrades AVITA Medical to Sell From Neutral, Price Target is $3 - MarketScreener
Earnings call transcript: Avita Medical Q2 2025 reveals revenue miss, stock tumbles - Investing.com Canada
Avita Medical stock downgraded to Sell by BTIG on reimbursement issues - Investing.com Canada
AVITA Medical, Inc. SEC 10-Q Report - TradingView
Avita Medical shares fall 31.97% premarket after revising earnings guidance for 2025. - AInvest
Avita Medical Q2 2025 slides: revenue grows 21% but guidance slashed on reimbursement delays - Investing.com Canada
AVITA Medical Inc (AVHHL) Q2 2025 Earnings Call Highlights: Reve - GuruFocus
Avita Medical (RCEL) Q2 Sales Up 21% - AOL.com
Avita Medical, Inc. Revises Earnings Guidance for Full-Year 2025 - MarketScreener
Transcript : AVITA Medical, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):